Progress of chimeric antigen receptor T cell therapy for T-cell lymphoma
10.3760/cma.j.cn115356-20240315-00036
- VernacularTitle:T细胞淋巴瘤的嵌合抗原受体T细胞治疗进展
- Author:
Sijia YAN
1
;
Yi XIAO
Author Information
1. 华中科技大学同济医学院附属同济医院血液内科，武汉 430030
- Keywords:
Lymphoma, T-cell, peripheral;
Chimeric antigen receptor T cell;
Molecular targeted therapy;
Immunotherapy
- From:
Journal of Leukemia & Lymphoma
2025;34(2):117-121
- CountryChina
- Language:Chinese
-
Abstract:
T-cell lymphoma (TCL) is a rare type of non-Hodgkin lymphoma. CHOP/CHOP-like regimens are commonly used to treat TCL, but the prognosis is poor. Chimeric antigen receptor T cell therapy has shown its unique advantages in B-cell lymphoma, while its efficacy in TCL is still unclear. Some studies on different targets are ongoing, providing new directions for treatment of patients with TCL.
